Assessment of Mortality Risk in Patients With Community‐Acquired Pneumonia: Role of Novel Inflammatory Biomarkers
Journal of Clinical Laboratory Analysis · 2025-09 · 39 (17)
DOI: 10.1002/jcla.70081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 13.08.2025. Verfasst von Burcu Baran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Diseases, Erciyes University Medical School, Kayseri, Turkey. Hauptthemen laut MEDLINE: Community-Acquired Infections, Biomarkers, Pneumonia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Pneumonia is a lung parenchyma infection with clinical presentations ranging from mild to life‐threatening. Its severity depends on factors such as the causative pathogen, the host's immune response, and existing comorbidities. This study aimed to investigate the prognostic value of novel inflammatory biomarkers for predicting in‐hospital mortality in patients with community‐acquired pneumonia (CAP).
Methods
This retrospective cross‐sectional study included 207 hospitalized patients diagnosed with clinically and radiologically confirmed pneumonia. Laboratory data collected upon admission included complete blood count parameters, C‐reactive protein (CRP), creatinine, and albumin levels. Systemic inflammatory biomarkers such as the neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), CRP‐to‐albumin ratio (CAR), CRP‐to‐lymphocyte ratio (CLR), systemic immune‐inflammation index (SII), systemic inflammatory response index (SIRI), prognostic nutritional index (PNI), and C‐reactive protein‐albumin‐lymphocyte (CALLY) index were calculated.
Results
The cohort was predominantly male (69%, n = 142) with a mean age of 62.1 ± 16.3 years. The median hospital stay was 8 days, with an 11% mortality rate. Malignancy was more frequent in the nonsurvivor group ( p = 0.001). Nonsurvivors had significantly lower hemoglobin ( p < 0.001) and albumin ( p = 0.004) levels, while CRP ( p = 0.024) and creatinine ( p = 0.002) were elevated. NLR ( p = 0.009), CAR ( p = 0.011), CLR ( p = 0.006), SII ( p = 0.013), and SIRI ( p = 0.024) were higher in nonsurvivors, while PNI ( p = 0.010) and CALLY ( p = 0.003) were lower.
Conclusion
Novel inflammatory biomarkers, particularly the CALLY index, are valuable for mortality prediction in CAP, aiding in risk stratification and early management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Diseases, Erciyes University Medical School, Kayseri, Turkey.
ORCID-Profile: Burcu Baran, Nur Aleyna Yetkin, Bilal Rabahoğlu, Nuri Tutar, İnci Gülmez
Zitieren
APA
Baran, B., Yetkin, N. A., Rabahoğlu, B., Tutar, N., & Gülmez, İ. (2025). Assessment of Mortality Risk in Patients With Community‐Acquired Pneumonia: Role of Novel Inflammatory Biomarkers. Journal of Clinical Laboratory Analysis, 39(17). https://doi.org/10.1002/jcla.70081
Vancouver
Baran B, Yetkin NA, Rabahoğlu B, Tutar N, Gülmez İ. Assessment of Mortality Risk in Patients With Community‐Acquired Pneumonia: Role of Novel Inflammatory Biomarkers. Journal of Clinical Laboratory Analysis. 2025;39(17). doi:10.1002/jcla.70081
BibTeX
@article{Baran2025,
author = {Baran, Burcu and Yetkin, Nur Aleyna and Rabahoğlu, Bilal and Tutar, Nuri and Gülmez, İnci},
title = {Assessment of Mortality Risk in Patients With Community‐Acquired Pneumonia: Role of Novel Inflammatory Biomarkers},
journal = {Journal of Clinical Laboratory Analysis},
year = {2025},
volume = {39},
number = {17},
doi = {10.1002/jcla.70081}
}
EUVIMED